Several studies have shown that mortality in people with epilepsy is 1.6 to 3.0 times greater than expected in the general population. A startling implication of this increased mortality is that, in general, persons who have epilepsy with known etiology lose 10 years of life compared with the general population; whereas persons whose epilepsy etiology is unknown lose 2 years of life. Epilepsy etiology is an important determinant of long-term mortality, as has been shown in the U.S. (1) and in the U.K. (2) with very similar results. Persons with unknown, genetic, or presumed genetic epilepsy etiology have a slightly increased mortality that is statistically significant in the U.S. study, but it is not significant in the U.K. study. Persons with neurologic deficits have a greatly increased mortality compared with that expected, and persons with remote symptomatic epilepsy also have an increased mortality. Etiology is also an important factor associated with mortality following status epilepticus (SE). Among 30-day survivors of SE, mortality is 29% in idiopathic/cryptogenic SE, 44% in remote symptomatic SE, and 73% in progressive symptomatic SE after 10 years of follow-up (3) .
Cardiovascular disorders are a major cause of increased mortality following epilepsy diagnosis. The risk of first stroke is increased by two-to seven-fold following onset of epilepsy of unknown etiology (4) (5) (6) . Other important causes of deaths in epilepsy are alcohol dependence and other drug dependence, which have been shown to be associated with an increased standardized mortality ratio (SMR) of approximately 25 and 13, respectively (7) .
The importance of seizure control as a determinant of long-term mortality was reemphasized in a recent populationbased study of childhood-onset epilepsy (8) . Predictors of mortality in that study were lack of 5-year terminal seizure remission, remote symptomatic etiology, history of SE, and epilepsy onset at age <2 years. With adjusted analysis, the sole predictor of mortality was the lack of 5-year terminal remission. Relevant to this finding is another study that found nonadherence to AED therapy is associated with three-fold higher mortality than adherence (9) . However, it is not known from this study whether or not the nonadherence caused seizure persistence, which in turn posed the higher mortality.
There are three epilepsy-related causes of death: accidents, SUDEP, and suicide. (Suicide will be discussed in a subsequent section.) The SMR for accidents is close to five (10) . The risk factors for accidents and injuries in epilepsy have been identified to be long duration of epilepsy, >3 AED adverse events, and increased seizure frequency (11) .
A surprising recent finding concerning SUDEP arises from a meta-analysis of 11 AED randomized, controlled trials, which revealed that patients who were allocated to take adjunctive placebo had a more than five times higher SUDEP risk than patients who were assigned to take adjunctive AED at efficacious doses (12) .
Epilepsy mortality may be reduced by the following clinical measures that address potentially modifiable risk factors: treating seizures lasting 5 minutes or longer to prevent status and its consequences; reducing stroke risk factors; offering alcohol and drug dependence treatment programs; screening for depression and history of suicide and offering treatment where needed; and counseling about the importance of seizure control and AED compliance.
Mortality in Childhood-Onset Epilepsy
Presented by Anne T. Berg, PhD The SMR in children with epilepsy in North America ranges from 5.3 to 9.0 (13) (14) (15) . As shown in a study conducted in the Netherlands, SMR is highest at 13 for persons with epilepsy onset in the first decade of life, and the rate falls to five in the second decade (10) . Combined data from four studies showed that the mortality rate in young persons with epilepsy is 260 per 100,000 per year (13) (14) (15) (16) . Half of all deaths occurred within 5 years of diagnosis. Three-quarters of those who died had moderately severe to severe cognitive impairment; whereas the rest had either only mild impairment or were normal. Those with complicated epilepsies had a morality rate of 857 per 100,000 per year, in contrast to those with uncomplicated epilepsies who had a rate of only 36 per 100,000 per year (i.e., "complicated" means association with structural brain lesion, neurometabolic condition, neurologic impairment, or intellectual disability; "uncomplicated" means normal examination, no intellectual disability, and no identified underlying cause of epilepsy.)
Respiratory disorder was the most common natural cause of mortality, accounting for nearly three-quarters of the deaths from natural causes. Ten of the total death cases were SUDEP. Whereas almost all of those who died of respiratory disorder or sepsis had moderately severe to severe cognitive impairment, SUDEP did not occur predominantly in the severely impaired group (i.e., <50% had moderately severe to severe cognitive impairment, and the rest had either mild or no impairment). However, the SUDEP rate was 96.5 per 100,000 per year for those with complicated epilepsies, and only 9 per 100,000 per year for those with uncomplicated epilepsies.
Against the backdrop of low childhood and young adult mortality in general, death rates in childhood-onset epilepsy are high. The majority of deaths are secondary to infections and complications of neurologic impairment, and there is no evidence of substantially increased risk from many preventable accidental causes of death. In uncomplicated epilepsy, SUDEP rates are comparable to death rates from the leading causes of early death in the general population. Rates of sudden death are as high as, or higher than, rates of common causes of death in young people (e.g., accidents, homicide, suicide, cancer, heart disease).
Suicide in Epilepsy: Identifying Risks and Steps to Prevention
Presented by Andres M. Kanner, MD Suicide accounts for approximately 12% of all deaths in epilepsy, as compared with about 1% of deaths in the general population (17) . The SMR for completed suicide is 3.5-5.0 (7, 18) . Compared with persons without epilepsy, persons with epilepsy have in general about 2.5 times higher risk for suicide (19) . The risk is further increased by the presence of psychiatric comorbidities: 32-fold in epilepsy persons with affective disorder, 11-fold in those with anxiety disorder, and 12-fold in those with schizophrenia.
Although the FDA has cautioned that AED use is associated with increased suicide risk, the absolute risk is yet to be established, and the risk, if any, should be balanced against the benefits of a particular AED for each individual. More studies are needed to better determine the magnitude of suicide risk attributable to specific AEDs. Nonetheless, certain AEDs could cause depression and anxiety in individuals at risk for psychiatric illness (e.g., people with a prior history or a family psychiatric history). These AEDs include barbiturates, topiramate, levetiracetam, zonisamide, and vigabatrin (20) (21) (22) (23) . Moreover, depression and suicide risk can be detected in persons with epilepsy by using self-rating screening instruments that patients can complete in the waiting room prior to their visit. In a series of 655 consecutive outpatients with epilepsy, the Neurological Disorders Depression Inventory in Epilepsy (NDDI-E) (24) detected possible major depressive episodes in nearly 18% of the patients, and possible generalized anxiety disorder in nearly 20% using the patient health questionnaire Generalized Anxiety Disorder-7 (GAD-7) (25) (A.M.K., unpublished data, XXXX). The Suicidality Module of the Mini-International Neuropsychiatric Interview (M.I.N.I.) (26) disclosed that about 5% of the patients have active suicidal ideation, and 1.5% have considered a suicide plan. The degree of suicide risk can also be assessed by using the above instruments, so that patients who are determined to be at high risk for suicide could undergo psychiatric care, which has been proven to reduce the risk. For example, among 117 consecutive patients, the number of high-risk patients identified by both the NDDI-E and the GAD-7, was reduced from 21 before psychiatric intervention to 9 after. The number of patients with active suicidal thoughts was reduced from eight to two (Kanner, unpublished data).
Prevention of suicide begins by identifying patients with current major depressive disorder with active suicidal ideation. Self-rating screening instruments can be completed in an epilepsy clinic at each visit. Referral for treatment is associated with improvement in comorbid mood disorder and suicidality. Identifying risks factors of suicide can be easily achieved in an outpatient epilepsy clinic. The most frequent obstacle to preventing suicide is not asking about it, or its risk factors.
Antiepileptic Drugs and Cardiovascular Disease
Presented by Scott Mintzer, MD The SMR for cardiac disease determined by several studies in persons with epilepsy ranges widely from 1.5 to 10.7 but is elevated above the general population in most studies (27, 28) . One U.S. population-based study has determined that the SMR for ischemic heart disease in persons with epilepsy age 25 to 44 years is 5.7, and the rate is 2.5 for those age 45 to 64 years (29) .
Consideration should be given to the idea that drugs, not the disease itself, may be responsible for this increased risk. AEDs are implicated because many AEDs induce CYP450 enzymes that participate in cholesterol synthesis. More than ten cross-sectional studies of adults and children have found elevated total cholesterol in carbamazepine-treated patients relative to controls or valproated-treated patients (30) . Likewise, a half-dozen studies of phenobarbital showed elevated cholesterol. Because of the cross-sectional design of these studies, the cholesterol increase cannot be definitively ascribed to AEDs. However, there have been a number of studies that measured lipids before and after carbamazepine treatment (31) . These studies have shown increases in total cholesterol of 20 to 25 mg/dL.
A prospective study measured the serologic markers of risk for vascular disease before and after conversion from enzymeinducing phenytoin or carbamazepine monotherapy to nonenzyme-inducing lamotrigine or levetiracetam monotherapy (i.e., lipid profile, homocysteine, and C-reactive protein [CRP]) (32) . The conversion resulted in significant reduction in total cholesterol (−24.8 mg/dL), atherogenic non-high-density lipoprotein cholesterol (−19.9 mg/dL), triglycerides (−47.1 mg/ dL), and CRP (−31.4%). Those who discontinued phenytoin had a significant reduction in homocysteine level (−1.7 µmol/L). In another study, conversion from carbamazepine or phenytoin therapy to non-enzyme-inducing topiramate resulted in a −35 mg/dL decline in total cholesterol and also significant declines in all cholesterol fractions, triglycerides, low-density lipoprotein (LDL) particle concentration, and over 50% in CRP concentration level.
The combined thickness of the intimal and medial layers of the carotid (IMT) as measured by ultrasound is a very potent surrogate marker for both cerebrovascular and myocardial infarction risks. There have been three separate studies showing increased carotid IMT in AED-treated epilepsy patients relative to controls. One study found that carbamazepinetreated patients had increased IMT compared with untreated patients (33) . Moreover, the degree of IMT has been shown to be positively correlated with the duration of carbamazepine, phenytoin, or valproate therapy (34) . The correlation was not significant in patients taking lamotrigine.
Compared with patients taking carbamazepine, patients taking valproate have been reported to have a 28% lower rate of myocardial infarction and 14% lower rate of cerebrovascular accidents (35) . Lamotrigine use is associated with 15% lower rate of cardiovascular deaths. Patients taking oxcarbazepine have a 21% higher rate of cerebrovascular accidents. An 8 to 10 percent increased rate of cardiovascular death was also observed in patients using oxcarbazepine or phenobarbital.
In conclusion, patients with epilepsy have higher rates of vascular disease. Enzyme-inducing AEDs exert deleterious effects on multiple surrogate markers of vascular risks, which could possibly increase the risk of myocardial infarction and other vascular disorders. At the minimum, patients taking enzyme-inducing AEDs need to be screened for vascular risks with lipid panel, cardiac, and carotid imaging. Conversion from enzyme-inducing AED to non-enzyme-inducing AED use should be considered when appropriate.
Summary of Session II: SUDEP-Where Are We Now?
Moderator: L. J. Hirsch
Summary of the NIH/National Institute of Neurological Disorders and Stroke SUDEP Workshop
Presented by Lawrence J. Hirsch, MD In 2007, the AES and the Epilepsy Foundation (EF) sponsored a joint task force on SUDEP. The published recommendations of this workshop (1) included convening a multidisciplinary conference on SUDEP, including experts outside of epilepsy and neurology. This led to the NIH/ National Institute of Neurological Disorders and Stroke (NINDS)-sponsored 3-day international workshop, results of which were published in 2011 (2) . Participants included those with expertise in cardiol-ogy, genetics, pathology, the autonomic nervous system, sudden infant death syndrome (SIDS), respiratory physiology, pathology, epidemiology, guideline development, patient advocacy, and bereavement. There were parallel sessions on scientific aspects (co-chaired by Elson So and Jeff Noebels) and education/advocacy (co-chaired by Jeffrey Buchhalter and Tess Sierzant).
Discussions on the pathophysiology of SUDEP led to general conclusions that there appears to be a prominent role of respiratory factors, including hypoxemia and central hypoventilation; a possible major role of central shutdown as identified by postictal EEG suppression; and a role of cardiac factors, including genetic predisposition to arrhythmias. A combination of these factors, and possibly others, is likely to play a role. Recommendations from the scientific sessions included performing an EKG in most if not all people with epilepsy and performing additional research related to SIDS risk factors (serotonin, exposure to tobacco smoke in utero, and others), the autonomic nervous system, respiratory drive, and the role of stimulation in the postictal setting, the predictive value of peri-ictal physiology including postictal EEG suppression, genetics of ion channels expressed both in the heart and brain, the utility of nocturnal supervision or monitoring devices, and how to improve case identification and reporting. Other specific recommendations were to create a SUDEP coalition, research consortia, a SUDEP registry, and standardized autopsy methodology with central tissue and DNA banks.
Recommendations of the education workgroup included educating all people with epilepsy about SUDEP as part of their overall education about the harm of seizures, except in rare extenuating circumstances. They also suggested investigating methods to determine when and how to best inform patients about SUDEP and creating standardized and widely available educational material.
Many of the recommendations have already begun. Sites for reliable additional information can be obtained via multiple Web sites, including www.aesnet.org/sudep; www. sudepaware.com (with free downloadable brochures); http:// www.epilepsyfoundation.org/aboutepilepsy/healthrisks/ sudep; and http://www.cureepilepsy.org/aboutepilepsy/ sudep.asp.
The Epidemiology of SUDEP: A Public Health Perspective
Presented by David J. Thurman, MD, MPH Only a few studies of the incidence of SUDEP in general populations have been published. At present, standard mortality data derived from death certificates are of little use in such research owing to the high frequency in which SUDEP is overlooked as a cause of death, as well as the lack of specific ICD-9 and ICD-10 codes for SUDEP. Therefore, valid population-based studies of SUDEP require separate, sensitive, and specific methods of case ascertainment, including active screening of suspect cases by medical examiners.
Among five population-based studies reviewed that meet such criteria for case ascertainment (3-7), the median reported incidence rate of SUDEP is approximately one case per 1,000 people with epilepsy per year. In comparison, a review of clinical cohort studies of patients with refractory epilepsy (8) (9) (10) (11) (12) (13) indicates a much higher risk in this subpopulation, yielding a median rate of six cases per thousand per year. The incidence of SUDEP also varies by age-appearing low in young children, rising steeply in adolescence, peaking in young adulthood, and declining substantially after age 50 years (7) . From these data, the lifetime cumulative incidence (lifetime risk) of SUDEP can be calculated (14) . Accordingly, across the population of all persons with childhood-onset lifelong epilepsy, the estimated lifetime risk of SUDEP (up to age 80 years) is nearly 7%. And, in the subpopulation of persons with childhoodonset epilepsy who have lifelong refractory epilepsy, the estimated lifetime risk of SUDEP is 35% (estimate slightly revised from number presented at the conference).
If applied to the U.S. population, the estimated incidence of SUDEP indicates nearly 2,000 SUDEP deaths per year. However, when comparing numbers of deaths among different causes, a more useful measure is the "years of potential life lost" (YPLL), which gives greater weight to deaths occurring at younger ages. For SUDEP, the YPLL is 73,000 per year (estimate slightly revised from number presented at the conference), which exceeds corresponding YPLL values for amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer disease, and Parkinson disease.
In conclusion, these findings demonstrate that SUDEP has a substantial public health impact and support arguments for increasing the response of the public health community, researchers, and clinicians to investigate and reduce the risk of SUDEP.
The Current State of SUDEP Awareness
Presented by Tess Sierzant, MS, RN, ACNS-BC Several key events have contributed to an increase of awareness among consumers and professionals in North America. The AES/EF Joint Task Force on SUDEP and the subsequent NIH-sponsored workshop led to the creation of The SUDEP Coalition, as it became clear that developing strong partnerships would be a key means to understanding and addressing the complexities of SUDEP. The Coalition's goal is to coordinate and advance the efforts of the many organizations and stakeholders. The EF's role with the Coalition is to lead the education and advocacy work. In May 2009, the group, composed of family members, affiliate representatives, healthcare professionals, and representatives from international epilepsy/ SUDEP organizations, met to continue to address the array of educational and advocacy needs.
Some of the key activities include assessing the EF Web site for SUDEP information, incorporating frequently asked questions (FAQs) about SUDEP, and creating an area dedicated solely to SUDEP; conducting a survey of the EF-affiliate network to determine what each is doing to address SUDEP and in what areas additional services or tools are needed; providing links with other organizations dedicated to SUDEP such as Epilepsy Bereaved, SUDEP Aware, and the Danny Did Foundation; and beginning a Twitter campaign. Two of the group members gave a presentation specifically for nurses at the American Association of Neuroscience Nurses Annual Meeting. A toolkit of information, which included the FAQs, recent publications, research, and other resources, was made available to all EF affiliates. Each of the affiliates received copies of Sudden Death in Epilepsy: Continuing the Global Conversation for distribution in their local areas.
EF offered $3,500 grants to the affiliates for the express purpose of increasing SUDEP awareness and providing community education. Twenty-eight affiliates took advantage of the grants. As part of EF's Research Initiative, they awarded a $50,000 research grant to study SUDEP risk factors.
Next on the agenda for the workgroup is to investigate the establishment of a family support network. It is critical that the affiliates continue to work at the grassroots of need and that partnerships are further cultivated in our efforts to increase awareness and get to the bottom of the conundrum that is SUDEP.
Revisiting the SUDEP Definition
Presented by Lina Nashef, MB, ChB There have been two widely used SUDEP definitions in use for the past 15 years or so (15, 16) . Any definition of SUDEP needs to be applicable in an operational setting and recognize not only the possibility of heterogeneous mechanisms underlying SUDEP but also different requirements of research studies, whereby some may need to be inclusive while others focus on "pure" categories. A new, unified definition of SUDEP (including the use of the word "unexpected" in the name, not "unexplained") was recently published (17) . This definition combines the two previously used definitions and clarifies areas of ambiguity. The term applies whether or not a terminal seizure occurred.
One significant change from the prior definitions is limiting the term "possible SUDEP" to those with competing causes of death, and classifying those with inadequate information available as "unclassified. " In addition, a new category of "SUDEP Plus" was created, to refer to cases that otherwise qualify as SUDEP, but in which there is a preexisting potentially contributing condition such as coronary artery disease without evidence of myocardial infarction. To be considered SUDEP, death should occur within 1 hour of a known terminal event.
To be excluded as SUDEP due to SE, seizure activity should be known to have lasted at least 30 minutes. Death occurring in water without submersion should be classified as "Possible SUDEP. " "Near-SUDEP" should include cases in which cardiopulmonary arrest was reversed by resuscitation, and the patient survived >1 hour.
Extensive examples of scenarios and how to classify them are provided in the publication by Nashef et al. (17) .
Summary of Session III: Clinical Research Methodology
Moderator: Elizabeth J. Donner, MD, FRCPC Clinician researchers are using several research methods to enhance our understanding of SUDEP. Studies of people living with epilepsy and those deceased by SUDEP demonstrate the benefit of multiple approaches to gain a better understanding of the mechanism and risk factors for sudden death in epilepsy.
Recording and Measuring Seizure-Related Physiology
Presented by Lisa M. Bateman, MD, FRCPC Many reports indicate that SUDEP is most often preceded by a seizure. The strongest risk factor for SUDEP is frequent, generalized tonic-clonic seizures, and in the majority of witnessed SUDEP cases, a seizure was seen immediately prior to death. The temporal relationship between death and a terminal seizure suggests that investigation of peri-ictal physiology may yield important insights.
To enhance patient safety in the Epilepsy Monitoring Unit (EMU) at the University of California at Davis Medical Center, an expanded array of monitoring equipment is used. All patients admitted to the EMU are monitored for oxygen saturation (SaO2), nasal airflow, thoraco-abdominal respiratory excursions, end tidal CO2 (ETCO2), and cardiac rhythm by threechannel EKG before, during, and after seizures. This monitoring protocol has allowed for detailed study of peri-ictal physiology.
Among 56 consecutive EMU patients, ictal hypoxemia (SaO2 < 90%) was recorded in one-third of partial-onset seizures. The mean duration of desaturation was 69.2 seconds with 10.2% of partial-onset seizure demonstrating a SaO2 < 80%, and 3.6% of partial-onset seizures demonstrating a SaO2 < 70%. Factors that increased the risk of desaturation include seizures of temporal lobe origin, seizures arising from the right hemisphere, seizures with spread to the contralateral hemisphere and male gender (1) . Cardiac repolarization abnormalities have also been documented in the peri-ictal period. Individual QTc intervals are abnormally prolonged and abnormally shortened with partial-onset seizures, more often with seizures associated with hypoxemia (2).
Studies of peri-ictal physiology permit a greater insight into the effect of seizures and may elucidate potential mechanisms of death related to SUDEP (3, 4) .
The MORTEMUS Experience
Presented by Torbjörn Tomson, MD, PhD
The MORTality in Epilepsy Monitoring Unit Study (MORTE-MUS) is a collaborative project that aims to quantify the risk of death, SUDEP, and "near SUDEP, " in patients with drug-resistant partial epilepsy during long-term video-EEG monitoring. This ongoing study is gathering cases of SUDEP and near-SUDEP for whom concomitant video, EEG, and EKG data are available with the ultimate goal to provide evidence regarding the respective role of cardiac and/or respiratory dysfunctions in the pathophysiology of SUDEP.
A survey regarding deaths and near-deaths of patients admitted to EMUs was distributed to all EMUs in Europe and Australia. One hundred fifty-six eligible EMU centers were identified, and 148 responses were obtained. Responses reflect an estimated total of 133,371 video-EEGs and 2,814 patientyears of monitoring. Nineteen deaths were identified, of which 14 were determined to be definite or probable SUDEP. In addition, six near-deaths were reported. These cases represent an incidence of 5 deaths per 1,000 patient-years during admission to the EMU. Incidence was higher (10.7 per 1,000) in the subset of adult patients undergoing presurgical evaluation.
Among the 14 cases of definite or probable SUDEP, there were 8 women. Mean age was 43 years with a mean duration of epilepsy of 16 years. Thirteen patients had a history of nocturnal seizures, and ten had a history of generalized tonic-clonic seizures. Twelve patients were not under direct supervision at the time of death. This is in significant contrast to the four patients with near-deaths and successful resuscitations, all of whom were under monitoring and supervision at the time of the near-fatal event.
This report highlights that patients admitted to EMUs are at significant risk of SUDEP. As such, patient supervision during EMU admissions is of critical importance.
Prospective SUDEP Case Collection and Registries
Presented by Orrin Devinsky, MD Clinical data derived from SUDEP cases can offer a rich data source to elucidate the clinical risk factors for SUDEP. The North American SUDEP Registry aims to create a standardized and valid methodology for identifying SUDEP cases across North America.
The registry will obtain clinical data, DNA, and tissue samples from SUDEP patients for use by the scientific community. Case identification will include surveillance for cases of SUDEP from a network of epilepsy centers and specific disease groups from which valid controls can be obtained. Clinical data will be collected via abstracted medical records and verbal autopsy, when needed. Collected data will include the medical history as well as the results of investigations including routine EEG, video-EEG, EKG, and neuroimaging.
To facilitate tissue collection, partnerships with existing tissue banks are being explored, including a partnership with the Autism Tissue Program, which has an established system for tissue collection. Once tissue is banked through the Autism Tissue Program, researchers may apply for tissue for scientific study. All tissue studies will undergo scientific review.
Establishing a national SUDEP registry will be challenging on several fronts. The first challenge is promotion of the registry among physicians, medical examiners, and coroners as well as advocacy organizations and the lay epilepsy community. It is necessary to explore the best methods to promote awareness of SUDEP and the registry in different communities, and encourage families to contribute clinical data and tissue. Family support will be critical and will include peer support from other affected families as well as more formal support through epilepsy advocacy groups. To further support SUDEP case collection, opportunities for state-or country-wide epilepsy reporting will also be explored.
Success of the North American SUDEP Registry will require broad collaboration and integrated efforts of lay and professional groups. Ultimately, a SUDEP Registry can enhance the capacity of scientists and clinicians to collaborate in understanding the mechanisms and targeting interventions to prevent SUDEP.
Controversies in SUDEP
Presented by Michael Pollanen, MD, PhD SUDEP is regularly encountered by the forensic pathologist, yet these deaths remain a mystery. Five key issues remain as barriers to SUDEP research in the domain of forensic pathology:
Nomenclature
Although SUDEP is a well-defined clinicopathologic entity, there is a lack of awareness of SUDEP nomenclature. This has a direct impact on the reliability of epidemiologic data on death certificates.
Overlap between SUDEP and other sudden death syndromes
Emerging evidence suggests that Sudden Arrhythmia Death Syndrome (SADS), SUDEP, and some cases of SIDS may all share a link. Limiting research to one of these three conditions may exclude important insights from similar cases.
Legislative barrier to research on autopsy samples
Clinical autopsies are performed with family consent. These are typically performed in cases of an expected death. In contrast, medical-legal autopsies are required by law in cases of an unexpected death in the community, which includes the majority of SUDEP cases. No consent is obtained for medical-legal autopsies. For this reason, it may be very difficult to obtain consent to perform research on autopsy samples.
Ethics of postmortem molecular diagnostics
The best practices for molecular autopsy are not yet determined. Should a molecular autopsy be part of a modern medical-legal autopsy? Is consent required for a molecular autopsy, since the autopsy itself is not performed under consent? Until these issues are resolved, routine molecular autopsy will not be realized.
Lack of forensic pathology research capacity
Coroners'/medical examiners' offices perform medical-legal autopsies. Most of these facilities are not linked to universities or academic health science centers. As such, most forensic pathologists are not able to focus on research efforts and lack the budget and time to support research.
Multidisciplinary solutions are required to overcome these challenges. Several initiatives are recommended to lift the barriers to SUDEP research:
1. Increase awareness of SUDEP.
Targeted information for coroners and medical examiners is critical to facilitate acceptance of the SUDEP nomenclature. 
Summary of Session IV: Strengthening SUDEP Research-A Shared Responsibility
Moderators: Tamzin Jeffs, MSc, and Alica Goldman, MD, PhD
With the steady rise in the mention of SUDEP in the scientific literature and growing public knowledge, the need to appreciate that there is a shared responsibility towards progressing research of mortality in epilepsy is becoming increasingly important. The role of stakeholders, their contribution, interaction, and collaboration are all integral to effective and efficient research. Through gaining an understanding of this shared purpose and improving our knowledge of research opportunities, the death investigation process, research recruitment procedure, and communication between stakeholders, SUDEP research may be strengthened and gain increased precedence.
Research Participation Opportunities Available to People With Epilepsy and Bereaved Families
Presented by Alica Goldman, MD, PhD
The role of family involvement in research studies and the collection of blood and tissue samples at autopsy were discussed. It was noted that individuals and families could provide a wealth of information through analysis of their DNA that could lead to the identification of genetic risk factors that predispose individuals to epilepsy and sudden death. These findings could play a vital role in finding the cause and prevention of SUDEP.
Coroner/Pathologist Role in SUDEP Research
Presented by Michael Pollanen, MD, PhD
The importance of detailed autopsies was explored in further detail. Limitations of this data were discussed such as the reality that postmortem antiepileptic drug levels are not necessarily indicative of the levels at time of death owing to factors such as decomposition, etc. Pollanen reported on a recent review of 24 SUDEP cases in Toronto (between 2005 and 2010; 11 males and 13 females, ranging from 19 to 65 years of age, with a mean age of 37 years) in which each individual was found dead at home, with just one having a witnessed collapse. He concluded that SUDEP is a robust clinical-pathologic entity that should be generally recognized by the medical profession. He also emphasized the importance of autopsies by pointing out that a SUDEP death cannot be definitively diagnosed without one. This provides families with a vital role in research, as often it is they who must provide the consent for an autopsy and the collection of blood and tissue for SUDEP research.
Support Needs of Study Participants and Resources Available
Presented by Jane Hanna, OBE Ms Hanna who is the director of Epilepsy Bereaved shared the benefit of her knowledge and 20 years experience providing support to families bereaved by epilepsy. She noted that many families find value and comfort in participating in research, by contributing towards change and making something productive come from their tragic loss. However, making the decision to participate can be daunting, fraught with questions and concern. The vital need for a specialist support service and the diversity of support needs were highlighted, with emphasis on a need to support a family's entire journey and not just the SUDEP event alone. In addition to participation, families also have an important role to play in the planning and design of future research projects and in ensuring that support provision is an integral part of research proposals and funding applications.
The Researcher and Family Support Network
Presented by Tamzin Jeffs, MSc
Ms Jeffs, executive director of SUDEP Aware, discussed the role of advocacy agencies in helping to provide this support to families. Drawing on the agency's 5 years of experience in North America, she explained their role in assisting researchers with their recruitment of families, providing support resources and services to researchers and families, and helping to facilitate communications between researchers, healthcare providers, the death investigation team, and families.
In summary, this session demonstrated how research is a joint effort and a shared responsibility between the stakeholders. Through working together to increase communication, collaboration, research participation, and funding, we may help to strengthen SUDEP research and bring us closer to finding the cause and prevention of SUDEP.
Summary of Session V: Research Methodology II -Bench Research-Ways to Study SUDEP
Moderator: Alica M. Goldman, MD, PhD
The aim of the session was to bridge the clinical and basic research presentations and to introduce and discuss the many levels of translational human research. The goal was to highlight the variety and the value of different model systems of SUDEP as integral and essential components in our investigations of SUDEP mechanisms in humans. The session purpose was to show and underscore how investigations in cellular or animal models and in patients complement each other and further our knowledge about epilepsy and its potential lethal complication.
SUDEP Research Involving Human Subjects
Presented by Lina Nashef, MB, ChB Dr Nashef described her pioneering clinical research on sudden death in epilepsy (1) . In her work, she coined the widely accepted working definition of SUDEP (2) and contributed to the current state of our understanding of the epidemiologic and genetic risk factors (3, 4) . She stressed the need for research on 1) SUDEP pathophysiology, 2) immediate interventions aimed to modify the currently known risk factors, and 3) effective interventions at vulnerable times. As an experienced investigator, Dr Nashef recognized that much human SUDEP research is not amenable to randomized studies and discussed ideas for alternative approaches.
SUDEP in Primate Epilepsy Models
Presented by Cassondra Bauer, PhD Dr Bauer described the Southwest National Primate Research Center of the Texas Biomedical Research Institute, which is a generally unknown and rare primate facility that houses close to 2,000 baboons. The primates and their families are a potentially valuable model system to study natural incidence, course, and consequences of idiopathic generalized epilepsy (IGE), which parallels human IGE (5) . The close phylogenetic and anatomic similarities to humans, the accessibility to close and comprehensive electrophysiological monitoring, and the detailed postmortem autopsy provide a unique opportunity to enhance research on SUDEP pathophysiology. Still, many logistic and ethical issues restrict the study of primates to focused scientific questions, and primates are inherently not suitable to use in performing or exploring genetic manipulations.
Value and Role of Mouse Models of SUDEP
Presented by George Richerson, MD, PhD Mouse models are uniquely poised for reciprocal translational research as demonstrated by Dr Richerson's laboratory, which has made important discoveries on the role of the serotonergic pathways in respiration, arousal, and SUDEP (6) . To help answer many research questions relatively quickly, mice have long been an invaluable tool in modeling human disease owing to many attributes: they are affordable, have a reasonable life span, and are relatively easy to manipulate genetically and pharmacologically. As mice have a rather homogenous background, experimentally induced genetic, therapeutic, and environmental effects can be measured and then translated back into human research. Dr Richerson clarified the value of mouse models in SUDEP research, described the many different kinds of available mouse models, and explained the contribution of the models in our study of the serotonin system, breathing, arousal, seizures, and SUDEP.
Exploration of SUDEP Mechanisms in Stem Cells
Presented by Jack Parent, MD, PhD
The obvious challenges in modeling the complexity of the human cellular environment and the human genome in an animal such as a genetically engineered mouse were described. Dr Parent detailed his laboratory's revolutionary research approach using induced pluripotent stem cells (iPSCs) to study human epilepsy. He walked through the apparent advantages of using iPSCs in studying human epilepsy including the fol-lowing: 1) cells are derived from each individual patient and thus represent a true personal genome and proteome; 2) the function of the human mutant gene can be tested directly and on the patient-specific background; 3) tested cells contain all naturally occurring accessory proteins that would otherwise affect the gene/protein function; and 4) the cultured cells provide an unlimited supply to study pathogenesis or to screen new compounds to identify novel treatments. Dr Parent emphasized the need for quality in fresh human tissue for the study of epilepsy and SUDEP.
Role of Human Tissue in Genetic Analysis of SUDEP

Presented by Alicia Goldman, MD, PhD
The importance of human tissue was the main focus of the final talk of the module. Dr Goldman emphasized the key role of human samples not only in research but also in diagnostics and future preventative screening of patients at risk. Any tissue can be a valuable resource, and a close collaborative relationship and open communication among patients, families, clinicians, and scientists is critical. The STOP SUDEP Program is an initiative supported by NINDS that is dedicated to brain and tissue banking donated through families affected by SUDEP with the purpose to promote SUDEP research and prevention.
In summary, this PAME conference module aimed to emphasize the following issues: 1) a comprehensive clinical monitoring and data collection will aid surveillance and investigations of SUDEP; 2) investigations in primates can parallel findings in humans and are to be considered in the study of SUDEP pathophysiology; 3) mouse models and pluripotent stem cell cultures allow molecular manipulations, often intimate investigations of SUDEP mechanisms, and rapid reciprocal translations of human research; and 4) molecular analysis of human tissues translates findings from model systems and provides a substrate for investigations of SUDEP mechanisms.
Summary of Session VI: Mechanisms I-Physiology
Moderator: George Richerson, MD, PhD
The physiology discussed in this section focused on the basic science data defining how death could be induced by a seizure. The three major goals of the session were to 1) understand why there is controversy about whether the primary cause of death in SUDEP is respiratory, cardiac, autonomic, or electrocerebral shutdown; 2) define changes in homeostatic physiological systems that occur during seizures; and 3) describe how these changes could lead to death. Two of the speakers focused on defects in respiratory control that are induced by seizures, two discussed changes in cardiovascular control that could be fatal, and one described new evidence on electrocerebral shutdown. A sixth speaker described parallels between SUDEP and SIDS. Three of the talks included data on how serotonin (5-hydroxytryptamine, 5-HT) is implicated in the pathophysiology of SUDEP.
Respiration, Seizures and SUDEP-Possible Prevention Approaches
Presented by Carl L. Faingold, PhD Data derived from a mouse model of SUDEP in which impaired breathing is a major cause of death after seizures. Evidence that both DBA/1 and DBA/2 mice exhibit seizure-induced sudden death (S-ISD) as a result of depressed respiration was discussed. Endogenous substances are released during generalized seizures, including 5-HT, which enhances respiration, and adenosine, which inhibits respiration. Therefore, the action of 5-HT drugs or adenosine on susceptibility to audiogenic S-ISD was evaluated in DBA mice. Mice that exhibited S-ISD were resuscitated. The DBA mice were given selective serotonin reuptake inhibitors (SSRIs), selective 5-HT receptor agonists, a 5-HT antagonist, or adenosine. SSRIs (fluoxetine and sertraline) blocked S-ISD but did not block seizures. A 5-HT 2B/2C agonist effectively blocks S-ISD in DBA/2 mice but not in DBA/1 mice, which may be owing to differences of 5-HT 2C receptor protein expression between these mice. A selective 5-HT 7 agonist was ineffective in both DBA/1 and DBA/2 mice. A 5-HT antagonist (cyproheptadine) or adenosine increased S-ISD in a group of DBA/2 mice that did not initially exhibit S-ISD. These findings indicate that many cases of SUDEP may be the result of a primary respiratory cause involving a defect in the 5-HT system. Several, but not all, drugs that enhance the action of 5-HT will block S-ISD in DBA mice, suggesting the possible use of SSRIs for prevention of human SUDEP, and that 5-HT antagonists should be avoided in epilepsy patients.
Molecular Mechanisms of Arousal and Breathing
Presented by Gordon F. Buchanan, MD, PhD
The emphasis of this presentation was on serotonergic mechanisms involved in arousal and breathing and their relation to SUDEP. The 5-HT is a well-known modulator of breathing and of sleep-wake regulation. The 5-HT neurons have been shown to be carbon-dioxide chemosensors that stimulate breathing and also induce arousal from sleep in response to an increase in inspired CO 2 . Evidence for this includes studies on 5-HT neurons in vitro in which a decrease in pH from 7.4 to 7.2 causes the firing rate to increase three-fold. Studies were performed on genetically modified mice in which serotonin neurons never develop within the central nervous system. These Lmx1b f/f/p mice lacking essentially all 5-HT neurons have an impaired ventilatory response to hypercapnia, about 50% of normal. Surprisingly, they also have impaired arousal from sleep in response to inspired CO 2 . In preliminary studies, these mice have been found to be more likely to die from acute seizures induced by pilocarpine or by maximal electroshock. In both cases, death is due to postictal respiratory dysfunction, and not to cardiac arrest or electrocerebral silence. These results suggest that drugs that enhance serotonin receptor activation may reduce the risk of SUDEP in humans.
Lessons Learned in SIDS Research: Do They Apply in SUDEP?
Presented by Hannah Kinney, MD The many similarities that exist between SUDEP and SIDS were highlighted. In both cases, individuals die suddenly and unexpectedly, a death-scene investigation and autopsy reveal no explanation of why death occurred, death often occurs after a sleep period, and the body is typically found in the prone position. During pathological examination of the brainstems of SIDS infants, findings include a decrease in 5-HT 1A receptor binding in the nuclei of the medulla that contain 5-HT neurons, as well as decreased levels of 5-HT, tryptophan hydroxylase, and 5-HT transporter binding and delayed maturation of 5-HT neurons. The mechanisms of death in SIDS are unknown, but like SUDEP, they have been proposed to be due to cardiac or respiratory dysfunction. The 5-HT system is involved in many aspects of cardiorespiratory control, so the 5-HT system abnormalities in SIDS cases are thought likely to contribute to the pathophysiology. Dr Kinney then discussed new data in which a small number of SIDS cases have been found to have hippocampal abnormalities. She raised the possibility that these infants may have had seizures that were undetected prior to birth and that they may have been the cause of death. Analogies were then made with sudden unexpected death in childhood (SUDC), which also shares some features with SIDS and SUDEP, and in which hippocampal abnormalities have been found in a subset. A subset of SIDS, SUDC, and SUDEP cases was proposed to be due to a "serotonopathy. " Evidence for this theory must come from further studies on additional pathological specimens of the three entities to determine whether 5-HT neuron defects are present in SUDC and SUDEP, and how commonly hippocampal abnormalities are found in SIDS. Regardless of the results of these future studies, the existing data suggest that drugs that target the 5-HT system may reduce the risk of SIDS.
Seizure-Related Cardiac Abnormalities Increase Susceptibility to Ventricular Arrhythmias
Presented by Steven L. Bealer, PhD Studies were described that suggest that respiratory distress may interact with cardiac abnormalities and arrhythmias to produce SUDEP. The probability of cardiac arrhythmias increases in hearts with ventricular repolarization abnormali-ties, such as a prolonged QT interval. It has been shown that chronic QT prolongation and increased susceptibility to arrhythmias are produced by the protracted seizures of SE. It was proposed that the repeated, self-limited seizures characteristic of epilepsy result in progressive increases in the QT interval, and the resulting susceptibility to arrhythmias, mimicking the responses observed following SE. Preliminary results were presented in which cardiac changes resulted from administration of repeated, self-limiting seizures in rats following hippocampal kindling. Animals given a total of 35-50 seizures had significant QT-interval prolongation and increased susceptibility to experimentally induced cardiac arrhythmias. These results are consistent with the proposal that an increasingly severe cardiac repolarization abnormality, characterized by a prolonged QT interval results from intractable seizures of epilepsy. This seizure-induced QT-interval prolongation could act as a cardiac substrate to increase the probability of lethal cardiac arrhythmias and SUDEP, which would be made worse in the setting of hypoxia.
Cardiac and Autonomic Functions in Epilepsy
Presented by Stephan Schuele, MD, MPH The challenge of research into a potential cardiac mechanism of SUDEP-in that epidemiologic studies of cardiac abnormalities as a risk factor for SUDEP are limited, and it is rare to directly observe cardiac deaths in epilepsy-was discussed. Nevertheless, the rising awareness of SUDEP in the last few years has stirred up an increasing interest in the cardiac function of patients with epilepsy and during seizures. Interictally, patients with epilepsy consistently show changes in heart rate variability, with a decreased high frequency (HF) index, suggesting alteration in vagal input. Ictal tachycardia can be seen in over 80% of seizures, and significant bradycardia in 2% that leads to asystole in 0.1 to 0.4 percent. Striking changes in electrodermal activity have recently been described that are associated with a diminished HF index, demonstrating a correlation between seizure severity and postictal EEG suppression. Ictal repolarization abnormalities, either in the form of ST segment elevation, alterations in the QTc interval or T-wave morphology have been described in patients with focal seizures, and even more often during secondarily generalized convulsions. However, in case-control studies, these changes do not predict an increased risk of SUDEP beyond the risk associated with generalized tonic-clonic seizures (GTCS). These and other data strongly suggest that cardiac abnormalities contribute to at least a subset of SUDEP cases, but prospective studies including cardiorespiratory monitoring are necessary to determine the sequence of events leading to death and effective ways to prevent cardiac SUDEP.
Electro-Cerebral Shutdown: Does Postictal EEG Suppression Play a Role in SUDEP?
Presented by Rainer Surges, MD Postictal generalized EEG suppression (PGES) frequently occurs after GTCS, displays a sudden onset, and has a mean duration of up to 90 seconds. PGES is associated with the severity of ictal hypoxemia and the tonic phase of the prior seizure.
The origin of PGES is unclear, but an active mechanism (e.g., via ictal activation of central inhibitory networks) is likely. PGES appears to be an electroencephalographic hallmark of SUDEP and is therefore thought to reflect an "electro-cerebral shutdown, " ultimately leading to fatal cardiorespiratory dysfunction. Of importance, PGES duration above 50 seconds has been reported to predict SUDEP. This finding, however, has not been replicated in another case-control study. Furthermore, PGES has had no major impact on cardiorespiratory function in seizures unrelated to SUDEP or near-SUDEP events. Patients who had seizures with PGES, however, were more frequently motionless or comatose and had more simple interventions by medical staff in the postictal state, suggesting that PGES may impair life-sustaining reflexes, thereby possibly facilitating SUDEP. In summary, the concept of electro-cerebral shutdown and the predictive value of PGES for SUDEP remain debatable at present. Future collaborative multicenter studies are required to elucidate the clinical significance of PGES in the pathophysiology of SUDEP.
Summary of Session VII: Talking About SUDEP
Moderator: Lina Nasheff, MD
Nursing Perspective
Presented by Tess Sierzant, RN Ms Tess Sierzant talked first about the nursing perspective in talking about SUDEP. She highlighted that there was only one U.K. questionnaire research paper looking at this subject, and that in this study, 56% of nurses reported discussing SUDEP with the majority or all of their patients, while 40% reported discussing SUDEP with few or none. The nurses also reported on the perceived response of patients/relatives. While on the one hand, the response included anxiety (49%), depressed mood (13%), anger (10%), and disbelief (23%); on the other hand, having a discussion about SUDEP was perceived to have resulted in improved adherence to treatment in 62%. In only 16%, was objection (to disclosure) reported by the family/caregiver, while 20% regretted being told. The perceived impact on quality of life was as follows: 42% improved, 41% no difference, and 18% worse. All clinical nurse specialists in epilepsy felt that patients should be told. Tess concluded that, while more research was needed to replicate these results in the United States and Canada and to determine the best way to deliver information on SUDEP, nurses were very well placed to provide such information to their patients within a multidisciplinary team. Of interest, she added that nurses were not afraid of discussing death with patients.
Physician Perspective
Presented by Elizabeth Donner, MD Dr Donner first cited a Canadian questionnaire survey on SUDEP knowledge, which showed that only 56% of Canadian pediatricians were aware that children with epilepsy were at increased risk of sudden death. She also cited two published European (U.K. and Italy) studies and the results of an unpublished North American survey of neurologists looking at self-reported practice with regard to "SUDEP disclosure. " In the U.K. study, those with a declared interest in epilepsy reported being more likely to discuss SUDEP, and those who reported doing so with all or most of their patients (31% of total) were less likely to report a negative reaction. Of the Italian neurologists surveyed, only 28% of respondents reported discussing SUDEP with all or the majority of their patients. In the North American survey, 1,200 responded to 17,558 questionnaires sent. A little more than half of respondents reported discussing SUDEP with their patients, some, most, or all of the time. Discussion rates were higher amongst those with a larger epilepsy practice and better knowledge of SUDEP. Barriers to discussion included lack of perceived significant risk, belief that risk could not be influenced, not yet having established a trusting doctor-patient relationship, risk-benefit ratio against disclosure, lack of time, insufficient information/knowledge of SUDEP, lack of support network for the patient, and information being available from other sources. Elizabeth concluded by highlighting opportunities for discussion in clinical practice.
What Families Want to Know
By Rajesh Ramachandran Nair, MD Dr Nair discussed that clinical practice should be guided by the families' views and reported on the results of an exploratory qualitative study that he and colleagues carried out using focus-group interviews with 36 parents of 21 children, and one-to-one interviews with six parents of four children who died suddenly. Although the majority, particularly mothers, had heard of SUDEP, this did not necessarily mean they had a good understanding of it, and there was a tendency to overestimate risk. There was unanimity among parents in favor of disclosure, generally at the time of diagnosis, face to face by the pediatric neurologist, with support from other healthcare professionals, and backed up by pamphlets and reliable Internet resources. There was a variable response from relatives in relation to whether the child should be informed, and parents wished to be involved in this decision. Rajesh and colleagues have secured additional funding for a second related project on how to translate these findings into clinical practice.
Ethics of SUDEP Disclosure
Presented by Nancy Collins, MD Dr Collins highlighted that in clinical decision making, aimed at maximum benefit and minimum harm, historical "paternalistic attitudes" have made way for "shared decision making, " with autonomy now having precedence over beneficence. Physician duty includes education and counseling of patients regarding their condition and prognosis, and this includes truth telling. She indicated that worries about catastrophic psychological harm from SUDEP disclosure were unfounded in the literature. There was evidence for the benefit of disclosing "bad news" or uncertainty, which allows for adjustment and adaptation. She highlighted the importance of a caring, emotionally supportive physician. Dr. Collins concluded that it was not a question of "if" but "how" SUDEP is discussed and stressed the need to tailor information to the individual patient or family. She cited exceptions to disclosure, where the physician is con-vinced disclosure would be harmful for the rare patient with unique, cultural, psychological, or social contexts.
An interactive discussion by the panel followed. The panel included the speakers as well as four members of lay organizations invited to join the panel in view of their knowledge of epilepsy and SUDEP, as well as personal experience of SUDEP, living with epilepsy, or caring for a child with epilepsy. On the panel were Jeanne Donalty, a member of the board of directors of Citizens United for Research in Epilepsy (CURE), whose son Christopher died of sudden death in epilepsy as a young adult; Barbara Kroner, a clinical epidemiologist at RTI International with research interests in epilepsy, the primary carer for her daughter Elizabeth, who has Aicardi syndrome, daily generalized seizures, and global developmental disabilities; Carrie McAteer-Fournier, associate director of DePaul University Internship Programme, who has lived with epilepsy since the age of 11; Michelle Welborn, president of Intractable Childhood Epilepsy (ICE) Alliance and doctor of pharmacy, whose daughter Lilly suffers from Dravet syndrome.
Many important points were raised. A few are highlighted. Jeanne told the audience that Christopher had not known about the risk of SUDEP. Had he done so, he may have made different choices, which could have influenced outcome. For example, he may have sought help, just before he died, when he felt at risk of having a seizure instead of choosing to be alone. Barbara and Michelle both felt that relatives had a right to know. How and when information was imparted were considered the key questions. Barbara felt she would have been overwhelmed if in addition to being given the devastating diagnosis (Aicardi syndrome), she was informed about SUDEP at the same time. Carrie was not informed about her own risk and found out gradually by herself. As a mother of a child with febrile seizures, she felt it very important to know, but she also highlighted that for a young person a time of special risk is when they are going to college. Nancy had highlighted the need to respect the patient's wish not to know and was asked to clarify this in relation to other information usually imparted. Jane Hanna commented that from a legal perspective, there is no "right not to know. " Currently, and although there is no legal requirement to tell, there are reportedly already four legal cases regarding lack of disclosure. The panel felt that the emphasis, nevertheless, needed to be on the patients' needs. In children, it is not clear when the child may be involved in a discussion about SUDEP. A member of the audience felt that doctors and nurses needed to be given more courses in communication. Jeanne encouraged those present to interact with families and be inspired by their experiences.
Summary of Session VIII: SUDEP Prevention
Moderator: Orrin Devinsky, MD
Prevention via Modifiable Risk Factors
Presented by Dale Hesdorffer, PhD Epidemiologic studies have identified several potentially modifiable risk factors for SUDEP, thereby suggesting strategies to help prevent SUDEP. Seizures, especially GTCS are most strongly associated with an increased risk for SUDEP. Therefore, seizure control is a primary focus of prevention, and an effec-tive treatment with AEDs is therefore likely to reduce the risk (1) . Complete seizure control is the goal, but this must be balanced against the side effects of AEDs and quality of life. Often, seizures cannot be fully controlled despite the best medical care. A meta-analysis of randomized AED clinical trials found that an adjunctive AED at an efficacious dose was associated with a seven-fold reduction in SUDEP compared with placebo (2) . Although these clinical trials were short-term and cannot be generalized to routine clinical care, they provide compelling evidence that improved seizure control reduces the rate of SUDEP, at least in the short term. Although lamotrigine is a risk factor for SUDEP in some studies, when analyses are adjusted for GTCS frequency, lamotrigine is no longer associated with a significantly increased risk for SUDEP.
Stimulation and Supervision for SUDEP Prevention
Presented by Derek Chong, MD Autopsies support that GTCS occur before most SUDEP. Cases of SUDEP witnessed in the community and recorded on video-EEG confirm this. Many patients continue to have GTCS and other seizures despite appropriate AED therapeutic regimens and patient education on AED adherence, sleep deprivation, avoiding excess alcohol, etc. It is unclear what can be done to prevent SUDEP after a seizure, as nothing has been proven to prevent SUDEP. However, studies found that SUDEP is more frequent when epilepsy patients are unsupervised, especially at night, as compared with when they are supervised during sleep with a monitoring device (e.g., sound monitor) or observed by someone who can respond and reposition them if needed (3) . Recent unpublished observations suggest that intervention by nurses in an EMU (Bateman L, 2012 unpublished observations) may shorten seizure duration and the severity and duration of postictal hypoxemia, ameliorating possible risk factors for SUDEP. However, well-designed studies are needed to address the role of repositioning, specific forms of stimulation, and the use of oxygen in preventing SUDEP. It is also important to understand why, rarely, seizures that occur in medical settings are followed by SUDEP despite prompt resuscitative measures (4) .
Roles of Devices in SUDEP Prevention
Presented by Daniel Friedman, MD Accumulating evidence highlights the occurrence of SUDEP after a GTCS in sleep with the patient in the prone position. Therefore, obstruction of the mouth and nose may contribute to the cascade of events that are ultimately fatal. Together with data that unsupervised patients are at higher risk of SUDEP, this suggests that devices to detect seizures and alarm caregivers could potentially prevent SUDEP. Several seizure detection devices are available and more are being developed. Studies on these devices remain limited, none are approved in the United States for seizure detection, and their role in preventing SUDEP remains unproven. Although EEG-based devices can offer high sensitivity and specificity, they are limited by difficulty with application and patient compliance. Most available devices are motion detectors, and include accelerometers (e.g., the following are commercially available as watches [SmartWatch, EpiLert], a phone app [EpDetect], mattress sensors [Medpage MP5, Emfit Movement Detector], or video motion detectors. They are inexpensive and noninvasive but detect only convulsive seizures and may have limited specificity. Several multimodal devices are being developed to detect combinations of motion, electrodermal skin response, heart rate, and respiratory rate (e.g., MIT-Boston Children's Hospital and RTI International). In addition, lattice pillows that allow airflow even if a patient's face is flush against the surface, are a class-I medical device in the U.K. but have never been tested for SUDEP prevention. Finally, seizure-detection devices are limited by the availability of a nearby caregiver who can respond and assist the person with epilepsy. Work is needed to develop systems that can detect seizures and prevent progression to SUDEP for those who live alone.
Role of AEDs in Preventing SUDEP
Presented by Torbjorn Tomson MD, PhD
As described above, AEDs are believed to play a powerful role in preventing SUDEP. In addition to the previously cited studies (1, 2) , additional evidence is relevant to this discussion. In a study that evaluated the effect of compliance with AED use, nonadherence was associated with a significantly increased risk of mortality (5) . A similar conclusion was drawn from a evaluation of filling the prescription for an AED (6) . An analysis of 42 randomized controlled trials using lamotrigine was performed. The total group included a total of 7,774 subjects in 13 parallel group, placebo-controlled, 17 parallel group active-controlled, and 12 crossover placebo-controlled trials (7) .
The results did not support a specific relationship between this lamotrigine and SUDEP.
Education as a Prevention Tool
By Rosemary Panelli, PhD Education on the occurrence and potential protective factors may be the most effective current tool to combat SUDEP. We need to better identify educational strategies that reduce seizure activity in different populations. This is particularly relevant in young adults, a population at high risk for nonadherence to AED therapy, sleep deprivation, and intermittent consumption of excess alcohol. Informed individual risk assessment may reduce not only SUDEP but also other causes of seizure-related death and morbidity. Educational strategies need to be comprehensive, addressing those responsible for the delivery of epilepsy care as well as the patient.
Summary of Session IX: Mechanisms II-Molecular and Genetic
Moderator: Jeffrey Noebels, MD, PhD This session focused on specific ion channel genes, molecular pathways, and cellular mechanisms of neurocardiac and neurorespiratory signaling defects contributing to SUDEP. In the introduction, moderator Jeff Noebels emphasized that there are known and clinically discoverable mutations of ion channel subunit genes linked to hyperexcitability in the neocortex, brainstem, and heart that are potential etiologies of SUDEP. Their epidemiologic prevalence is only beginning to be explored but they clearly represent opportunities for therapeutic intervention to reduce mortality.
Molecular Mechanisms in Sudden Cardiac Death and SUNDS
Presented by Matteo Vatta, MD Dr Vatta explored the area of sudden cardiac death (SCD), the leading cause of sudden death in the United States (300,000/ year). The majority of SCD is due to coronary vascular disease, while arrhythmogenic death, resulting from various patterns of defective cardiac repolarization (e.g., Brugada Syndrome, Long QT Syndrome), comprises about 5%. These syndromes are due to mutations in sodium channel (SCN5a) and potassium channel (KVLQT1) genes, and about 15 other cardiac voltage-gated channels in the heart, some with age-and onset-specific phenotypes (sudden unexpected nocturnal death-SUND). These may be de novo or familial and are sometimes associated with epilepsy or syncope.
Neurocardiac Molecular Mechanisms in SUDEP
Presented by Jeffrey Noebels, MD, PhD
The anatomic pathways leading from the cardiac representation in the temporal lobe to the vagal brainstem nuclei, and the two mouse models that illustrate how single ion channel mutations lead to SUDEP, were described. The first gene demonstrated to link epilepsy and cardiac arrhythmia is the long QT gene KVLQT1. The gene is present in both heart and brain, and mice with genetically engineered human LQT mutations have temporal lobe epilepsy, arrhythmias, and sudden death, as do human SUDEP cases. A second mechanistic category is represented by mice with mutations in Kv1.1, a different potassium channel expressed in brain and vagal nerves, but not in heart. The Kv1.1 knock-out mice show severe epilepsy, vagally mediated cardiac arrhythmias, and sudden death. Isolated axons from the vagus demonstrate ectopic firing that can be attenuated by the Kcnq1 potassium channel opener, flupirtine, demonstrating a potential new treatment strategy for reducing SUDEP risk in individuals with autonomic hyperreactivity. These discoveries reinforce the overriding need to raise the index of suspicion of potential SUDEP risk in all individuals with epilepsy and look repeatedly for ECG evidence of cardiac arrhythmias both at diagnosis and during pharmacologic management of epilepsy.
Genetic Variations in SUDEP
Presented by Alica Goldman, MD, PhD Dr Goldman described the most common patterns of genetic variation in human genomic analysis studies, and the powerful tools currently in use to isolate and analyze specific pathogenic mutations. Typical strategies involve screening in a population at risk, beginning either by interrogating known disease genes, an expanded list of candidate genes, or the entire genome (exonic or whole genome sequencing or copy number variant [CNV] analysis). The LQT genes have been extensively analyzed in cardiology using these techniques, and a broad spectrum of mutation types has been discovered, primarily in patients with syncope. The complexity of individual patterns and the still nascent field of predicting genotype-phenotype pathogenicity from a sequence variant represent the major challenge to the field of SUDEP risk prediction.
Role of KCNQ Channels in the Regulation of Respiratory Drive: Potential Implications for SUDEP
Presented by Daniel Mulkey, PhD
The functional pathways of chemoreception and the emerging role of KCNQ potassium channels in the regulation of excitability in this pathway were discussed. Central apnea is a common cause of seizure-related hypoxia and the potential for sudden death. The brainstem RTN nucleus is a key rhythm generator in the respiratory pathway linking peripheral blood O 2 chemosensors with respiration rate and depth and is modulated by the neurotransmitter serotonin. KCNQ channels in the RTN neurons contribute to this reflex by regulating tonic activity as shown in brain slice experiments and influence baseline breathing and the responsiveness of CO 2 in rodents in vivo. These channels play an essential role in setting respiratory drive and link the control of excitability in heart, brain, and respiratory pathways in a single therapeutic target.
Seizure-Induced Cardiac Remodeling
Presented by Anne Anderson, MD Dr Anderson introduced the downstream effects of seizures on the homeostatic plasticity of ion channels in the heart. Ion channel remodeling is a major use-dependent feature of the myocardium and enables both adaptive and maladaptive changes in rhythm generation and contractility to arise as a result of chronic seizure activity. In a rat pilocarpine model of chronic temporal lobe epilepsy, seizure-induced cardiac remodeling was studied using ECG, cardiac echo, biochemistry, and ex-vivo optical mapping of cardiac depolarization. This model shows premature lethality associated with a spectrum of cardiac changes: baseline tachyarrhythmia, altered ECG morphology, prolonged QT interval, shorter action potential duration, and slower conduction velocity, ectopic depolarizations, and changes in α-and β-noradrenergic receptor expression levels and Kv4.x potassium channels compared with the hearts of nonseizing control animals. These findings reinforce the need to follow cardiac function in patients with epilepsy by surveillance of the ECG during medical management of a chronic seizure disorder and therapy when indicated to minimize SUDEP risk.
Summary of Session X: Where Do We Go From Here?
Moderators: Jeffrey Buchhalter, MD, PhD, and Gardiner Lapham, RN, MPH The objectives of this session included the following: 1) promote discovery-basic mechanisms; clinical risk factors, biomarkers; translation-interventions; 2) facilitate mechanisms helping providers deliver the necessary information to their patients; 3) educate patients, families, and concerned individuals as to the risk of SUDEP. The first three talks explored federal, private, and industry sources of funding to promote discovery. These were followed by a presentation regarding the manner in which the public could become involved in expanding public awareness and action. The final discussion described development of SUDEP guidelines that address medical provider education.
Federal Funding for SUDEP, Research Priorities, and Opportunities for Collaboration
Presented by Vickey Whittemore, PhD Dr Whittemore described how the Centers for Disease Control (CDC)/NIH budget for SUDEP research was less than $500,000 prior to 2011 and greater than $2 million in the last 2 years, distributed through multiple NIH programs. In specific, two P20 planning grants were awarded "Predictive Genes, Mechanisms, and Clinical Biomarkers of SUDEP, " Jeffrey Noebels, principle investigator (PI), Baylor College of Medicine, and "Prevention and Risk Identification of SUDEP Mortality-the PRISM Project" S Lhatoo (PI), Case Western Reserve University. The NIH/CDC SUDEP efforts are focused on determining risk factors, identifying the underlying causative mechanisms, and developing protocols for biospecimen collection and have initiated surveillance for mortality in epilepsy by involving the medical examiners in select states. It was suggested that national SUDEP investigations learn from and potentially share resources with the currently ongoing Sudden Unexpected Infant Death (formerly SIDS) and the Sudden Unexpected Death in the Young registries. It is hoped that the latter registry will provide additional information regarding the frequency of SUDEP and risk factors, in addition to contributing to a biospecimen bank.
Opportunities for Private Sector Funding and Why Seed Funding Still Matters
Presented by Barbara Kelly, BA Ms Barbara Kelly, representing Citizens United for Research in Epilepsy (CURE), described the impact of the private sector on research funding. She noted that this organization was founded by three parents affected by epilepsy in their families to promote research by funding research aimed at the goal of "no seizures, no side effects. " A focus on SUDEP was driven by the determination of parents who had lost their children to epilepsy. Since 2004, their efforts have resulted in 15 awards, totaling more than $1.25 million to investigators, providing seed funding for SUDEP-related research. This support has led to larger government-funded initiatives. The results of CURE-funded research have provided important insights into cardiac, respiratory, and cerebral risk factors; established a pediatric SUDEP registry; explored the roles of serotonin and adenosine with implications for the use of selective serotonin uptake inhibitors; and led to the discovery of possible causative genes. Past and current research studies can be found on the CURE Web site at http://www.cureepilepsy.org.
Opportunities and Challenges for Industry to Advance Therapies
Presented by Roger Porter, MD Dr Roger Porter provided important insights into the role of industry and collaboration with the NINDS in bringing new antiepileptic drugs to market. He noted that industry confronts the issues of an ever-increasing regulatory environment, the need for cost containment as well as aligning molecular discoveries with market opportunities. The sequence of events entailed in making a new drug available includes discovery of the biological compound of interest, preclinical testing (laboratory and animal), human trials (phase 1, 2, and 3), and FDA approval (typically taking as long as a decade or more). The reality is that for every 5,000-10,000 compounds that enter the drug evaluation process, 250 will go through preclinical testing, 5 through clinical testing, and only 1 will eventually received FDA approval.
A key component of preclinical testing is the Anticonvulsant Screening Program that has screened almost 30,000 compounds since beginning in 1975 and more than 2,000 in 2011 alone. It was emphasized that the pharmaceutical industry is populated by companies of various sizes from the small biotechnology entities focused on early stage research and development to "Big Pharma" with fully integrated research, manufacturing, sales, and marketing divisions. The importance of industry in drug development is illustrated by the total investment in research spending in 2011 with the NIH and the Pharmaceutical Research and Manufacturers of America member companies investing $30.9 billion and $49.5 billion, respectively.
State of SUDEP Guidelines Development and Other Opportunities to Advance Best Practices
Presented by Cynthia Harden, MD Dr Cynthia Harden presented a summary of the current state of guidelines related to SUDEP. Of note, Dr Harden chairs a combined workgroup of the American Academy of Neurology and the European Federation of Neurological Sciences. Thus, importance of these guidelines with regard to professional awareness of SUDEP and improved quality of care cannot be overstated. The rationale for guidelines, including the importance of systematic review of the available literature and thereby the assessment of the benefits and risks of available treatment options, was discussed. It was emphasized that the literature reviews and assessment of evidence are based on predetermined criteria to highlight studies in which data were collected in an unbiased, randomized, controlled fashion, wherever possible, as opposed to case reports. This is in line with the U.S. Congress tasking the Institute of Medicine to create rigorous standards for practice guidelines in 2008. The development of guidelines for SUDEP is in the context of a similar, previous effort in the U.K. by the National Institute for Clinical Excellence (NICE). The NICE guidelines for epilepsy that were updated in January 2012 contained several key elements (1). The first key concept was the requirement that SUDEP be discussed as part of the epilepsy education plan. The second proposed a method for decreasing SUDEP by optimizing therapeutic efforts and being cognizant of the particular risks associated with nocturnal seizures. The third was that the information should be tailored in a fashion best suited to the needs of the individual patient and family. The American Academy of Neurology guideline process is focused on determining the frequency of SUDEP and risk factors related to its occurrence. A preliminary analysis reveals the presence of generalized tonic-clonic seizures, the frequency of GTCS, and poly-drug therapy (all markers of severity) are consistently associated with an increased risk of SUDEP (2) (3) (4) .
Forming a Collation to Advance Public Awareness-Opportunities for Involvement
The agenda for the immediate future is to increase awareness and understanding of SUDEP, ensure that accurate information is available to the public, encourage the discussion of mortality related to epilepsy, champion the need for increased resources for research, and assist in the identification of SUDEP deaths. Several means of increasing public awareness to achieve these goals were discussed. One of the most lay accessible publications available online describing SUDEP is Sudden Unexpected Death in Epilepsy, Continuing the Global Conversation (5) . The book contains chapters on the clinical and basic science aspects as well as the needed advocacy for SUDEP written by international experts. This publication is made available at no charge by Epilepsy Australia, the International Bureau for Epilepsy, and SUDEP Aware, demonstrating how an international collaboration can produce a powerful educational resource for the public. Another nonprofit organization has emerged devoted to patient education and advocacy in North America, SUDEP Aware, of which Ms Jeffs is the executive director. SUDEP Aware provides up-to-date information regarding research, support, and public awareness (6) . Recently, they have made available four eBrochures titled "Information for . . . " People with Epilepsy, Young Adults and Teens, People Bereaved by Epilepsy, and Healthcare Providers. Again, these are without charge and available for download on the SUDEP Aware Web site. These materials are part of a larger public awareness campaign: Making Sense of SUDEP (7) .
